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Abstract
Background This study aimed to evaluate the cardiac
outcome for children with microdeletion 22q11.2 and
congenital heart defect (CHD).
Methods A total of 49 consecutive children with 22q11.2
and CHD were retrospectively identified. The CHD con-
sisted of tetralogy of Fallot and variances (n = 22),
interrupted aortic arch (n = 10), ventricular septal defect (n
= 8), truncus arteriosus (n = 6), and double aortic arch (n =
1). Extracardiac anomalies were present in 46 of 47
children.
Results The median follow-up time was 8.5 years (range,
3 months to 23.5 years). Cardiac surgical repair was per-
formed for 35 children, whereas 5 had palliative surgery,
and 9 never underwent cardiac surgery. The median age at
repair was 7.5 months (range, 2 days to 5 years). The mean
hospital stay was 35 days (range, 7–204 days), and the
intensive care unit stay was 15 days (range, 3–194 days).
Significant postoperative complications occurred for 26
children (74%), and surgery for extracardiac malformations
was required for 21 patients (43%). The overall mortality
rate was 22% (11/49), with 1-year survival for 86% and 5-
year survival for 80% of the patients. A total of 27 cardiac
reinterventions were performed for 16 patients (46%)
including 15 reoperations and 12 interventional catheter-
izations. Residual cardiac findings were present in 25
patients (71%) at the end of the follow-up period.
Conclusions Children with microdeletion 22q11.2 and
CHD are at high risk for mortality and morbidity, as
determined by both the severity of the cardiac lesions and
the extracardiac anomalies associated with the
microdeletion.
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Deletions within chromosome band 22q11.2 are the most
common cause of DiGeorge syndrome (OMIM #188400),
velocardiofacial syndrome (OMIM #192430), and conotr-
uncal anomaly face syndrome (OMIM #217095) [11, 20].
Microdeletion 22q11.2 is estimated to occur in 10 to 23 per
100,000 live births, mostly as a de novo deletion [16, 25].
When the condition is familial, the inheritance pattern is
autosomal dominant [26]. The clinical spectrum of the
microdeletion 22q11.2 syndrome is wide, ranging from
subtle isolated findings to severe multiorgan involvement
[4]. Congenital heart disease (CHD) is a major feature of
this syndrome, as well as velopharyngeal anomalies, facial
dysmorphisms, and learning disabilities [4, 26]. The most
common cardiac lesions observed are conotruncal malfor-
mations, consisting of tetralogy of Fallot and its variances,
interrupted aortic arch type B, and truncus arteriosus
communis [13, 14].
The prevalence of 22q11.2 deletions in conotruncal
defects and the overall clinical features of this syndrome
have been extensively investigated [13, 14, 16, 26].
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However, information about long-term follow-up evalua-
tion and outcome of these patients is scarce.
Our study aimed to assess the clinical course and out-
come for children with deletion 22q11.2 and CHD, with an
emphasis on cardiac outcome.
Materials and Methods
This retrospective cohort study investigated all children
with CHD and microdeletion 22q11.2 who received their
diagnosis and treatment at our hospital during the past 25
years. The computer database for the division of cardiology
and medical genetics was used to identify all patients with
microdeletion 22q11.2 and CHD. The clinical records for
each patient were analyzed for diagnosis, treatment, clini-
cal course, and outcome, with special attention paid to
cardiac findings as well as related diagnostic and thera-
peutic interventions. Cardiac diagnosis was achieved
primarily by echocardiography using generally accepted
standard views. A diagnostic cardiac catheterization was
performed if echocardiographic information was not
complete.
Residual cardiac lesions were defined as significant if
the cardiologist performing echocardiography described
the lesion as being at least moderate. Lesions described as
trivial or mild were not considered relevant.
Genetic Screening
Patients with conotruncal malformations or other CHD
associated with typical facial dysmorphisms or extracar-
diac abnormalities were selected originally for screening of
chromosomal anomalies and microdeletion 22q11.2. Thus,
genetic testing was indicated on the basis of the CHD for
41 patients and on the basis of extracardial anomalies for 8
patients. These anomalies consisted of facial dysmorphism
and rhinolaryngologic findings in five patients, immuno-
deficiency with recurrent infections in two patients, and
hypoparathyroidism in one child.
Fluorescence in situ hybridization (FISH) analysis,
available in our institution since 1994, was performed
using the standard technique previously described [13]. For
18 patients born before 1994, the presence of microdeletion
22q11.2 was suspected and confirmed during follow-up
evaluation.
Statistical Analysis
Quantitative data are expressed as mean ± standard
deviation or as median and range as appropriate. The
data of four children who had a delayed referral for
cardiac evaluation and therefore a delayed cardiac diag-
nosis were not included in the demographic statistics.
This study was approved by the Ethics Board of our
institution.
Results
Clinical Findings and Genetics
Between July 1978 and June 2003, 49 children with mic-
rodeletion 22q11.2 and CHD were identified
retrospectively. The median age at cardiac diagnosis was 3
days (range, 0–94 days), and the median weight was 2.9 kg
(range, 1.3–4.8 kg). The gender distribution was equal
(49% males).
Congenital Heart Disease. The Cardiac Diagnoses are
Shown in Table 1.
Aortic arch anomalies were present in 24 patients,
including 12 right aortic arches and/or 15 aberrant sub-
clavian arteries. These anomalies represented the most
frequent additional cardiac findings.
Ventricular septal defect was associated with additional
cardiac lesions in seven of eight patients. These lesions
consisted of a right aortic arch in three patients and an
atrial septal defect in four patients.
For complete cardiac diagnosis, cardiac catheterization
was required in addition to echocardiography for 25 (51%)
of the 49 patients. A prenatal cardiac diagnosis was
achieved for three fetuses.
Cytogenetics
Parental genetic screening with FISH analysis was per-
formed in 35 (71%) of the 49 cases, demonstrating the
presence of a parental deletion in two cases. Thus, a de
novo deletion 22q11 was found in 33 (94%) of 35 cases.
Extracardiac Anomalies
Extracardiac anomalies, described in all but one patient
(Table 2), ranged from isolated craniofacial dysmorphisms
to lethal multiple malformations. In 13 cases (26%), ex-
tracardiac anomalies required invasive diagnostic
examinations, including laryngotracheobronchoscopy for
12 children and esophagogastroduodenoscopy for 2 chil-
dren. Six patients underwent more than one investigation.
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Clinical Management
Cardiac surgery was performed for 40 of the 49 patients.
The management algorithm is shown in Fig. 1. Repair of
CHD was achieved for 35 patients, including 10 repairs
after previous surgical palliation. Palliation comprised
insertion of a Blalock-Taussig shunt in five children, an
aortopulmonary shunt with unifocalization of the pulmon-
ary arteries in three children, and pulmonary artery banding
in two children. Repair could not be performed for five
palliated patients due to the premature death of three
children and anatomic vascular findings precluding repair
for two children. In these cases, palliation consisted of a
central aortopulmonary shunt in three patients and a right
ventricular to pulmonary artery shunt in one patient.
Repeated interventions, including a Blalock-Taussig shunt
once and a central shunt with unifocalization twice, were
performed for the fifth patient.
Cardiac surgery could not be performed in nine cases.
Five patients presented with a cardiovascular anatomy not
suitable for surgery. Three patients died of major extra-
cardiac malformations or major complications before
surgery (Table 3), and another patient showed spontaneous
closure of a ventricular septal defect.
The data concerning cardiac surgical repair are shown in
Table 1. Postoperative complications prolonging intensive
care unit (ICU) stay to more than 10 days occurred for 24
patients after 26 cardiac operations. Seven patients (14%)
required tracheotomy: secondary to tracheobronchial mal-
formations in four patients and because of prolonged
ventilatory support in three patients. One child presented
Table 1 Diagnosis and surgical repair of congenital heart defect
(CHD)a
Diagnosis CHD n = 49 n (%)
Tetralogy of Fallot 22 (45)
TOF/RVOT obstruction 10
PA/VSD, Fallot type 4
PA/VSD, MAPCAs 7
Absent PV syndrome 1
Interrupted aortic arch type B 10 (20)
Ventricular septal defect 8 (16)
Truncus arteriosus communis 6 (12)
Double outlet right ventricle 2 (4)
Double aortic arch 1 (2)
Surgical repair of CHD n = 35
Age at total repair: months (range) 7.5 (2 d to 5 y)
Weight: kg (range) 6.6 (2.7–16.5)
Hospitalisation: days (range) 35 (7 d to 7 mo)
ICU stay: days (range) 15 (3 d to 6.5 mo)
Complications of cardiac surgery:
n (%)
26 (74)
TOF, tetralogy of Fallot; RVOT, right ventricular outflow tract; PA,
pulmonary atresia; VSD, ventricular septal defect MAPCAs, major
aortopulmonary collaterals; PV, pulmonary valve; ICU, intensive care
unit
a Continuous data are given as median (range)
Table 2 Extracardiac anomalies and related surgical interventions in
49 children with microdeletion 22q11.2 and congenital heart defect
(CHD)
Extracardiac anomalies n (%)
Dysmorphisms and growth
Facial dysmorphic features 36 (73)
Weight £3P 18 (37)
Lenght £3P 14 (29)
Immunohematologic findings
Lymphocytopenia 30 (61)
Thymus aplasia 15 (31)
Thrombocytopenia 7 (14)
Neurologic findings
Abnormal muscle tone 26 (53)
Abnormal neuroimaging 16 (33)
Seizures 9 (18)
Neurodevelopmental delay 33 (67)
Endocrinologic findings
Hypocalcemia 21 (43)
With seizures 2 (4)
Rhinolaryngologic findings
Pharyngeal, laryngeal anomalies 19 (39)
Hearing impairment 11 (22)
Speech deficiency 9 (18)
Renal anomalies 10 (20)
Skeletal anomalies 5 (10)
Ophtalmologic anomalies 2 (4)
Surgical interventions n = 32 (n)
Velopharyngoplasty 8
Herniotomy 7
Diaphragmatic plication 3
Gastrostomy 3
Fundoplication 2
Laparotomy 3
Cricoid splitting 2
Orchidopexy 1
Fasciotomy 1
Cholecystectomy 1
Duodenostomy 1
Corneal transplantation 1
Probing of ductus nasolacrimalis 1
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with severe gastrointestinal complications involving bowel
perforation and necrosis, which required bowel resection
and caused a prolonged clinical course in the hospital. The
remaining patients experienced more than one postopera-
tive complication, mainly related to heart surgery,
including prolonged cardiac low output, arrhythmias,
thrombosis, chylothorax, diaphragmatic palsy, pneumonia,
renal failure, and sepsis. In all these cases, the cause for a
prolonged ICU stay was multifactorial, and one single
reason for it retrospectively was not identifiable.
For 21 children (43%), 32 noncardiac surgical inter-
ventions were required (Table 2). A total of 25 operations
(78%) were related to extracardiac anomalies associated
with the microdeletion 22q11.2, and 7 (22%) were related
to postoperative complications after cardiac surgery. Lap-
arotomy was required after perioperative iatrogenic
intestinal perforation in one patient and because of post-
operative intestinal necrosis in another patient (described
earlier). Fasciotomy was performed for a girl with post-
operative ischemic compartment syndrome in the lower
leg. In one patient with a choledocus anomaly, a cholestatic
syndrome and pancreatitis developed, requiring cholecys-
tectomy and duodenostomy.
Outcome
The median follow-up time was 4.8 years (range, 2 days to
24 years). The median age of the survivors at the end of the
follow-up period was 8.5 years (range, 3 months to 24
years). Follow-up information was complete for 48 of the
49 patients.
Survival
Overall mortality was 22.4% (11 of the 49 patients). The
survival rates were 86% for 1-year survival, 80% for 5-year
survival, and 78% for 10-year survival (Fig. 2). Higher
mortality was observed during the neonatal period (median
age, 7 days) and at the midterm follow-up point (median
age, 5 years). The cause of death was cardiac related in six
children, with three patients dying perioperatively, and not
cardiac related in five cases (Table 3). Considering the
cardiac diagnosis of the deceased patients, we found
mortality rates of 36% for pulmonary atresia and ventric-
ular septal defect, 30% for interrupted aortic arch, and 33%
for truncus arteriosus. No patient with tetralogy of Fallot
and right ventricular outflow tract obstruction died, and the
patient with an isolated ventricular septal defect died of
extracardiac causes.
Reinterventions
For 16 (46%) of the 35 patients who underwent total repair,
27 cardiac reinterventions were required (Table 4). Five
patients required more than one reintervention. Reinter-
ventions consisted of 15 reoperations and 12 interventional
catheterizations. The indications for reintervention are
summarized in Table 4. The median interval between
surgical repair and reintervention was 6 months (range, 18
days to 13 years). Reintervention-free survival was 75%
after 1 year, 70% after 2 years, and 64% after 10 years
(Fig. 3). At the end of the follow-up period, significant
residual cardiac lesions were observed in 27 (71%) of 38
survivors and in 24 (68%) of 35 corrected patients.
Extracardiac Follow-up Assessment
Neurologic abnormalities represented the most frequent
extracardiac findings during mid- to long-term follow-up
period. Neurodevelopmental delay was described for 32
patients (66%) and abnormal morphologic findings at
neuroimaging for 16 patients (33%). Among the hemato-
logic complications, lymphocytopenia (less than 1,000 G/l)
and thymus aplasia were of clinical relevance, particularly
during the first months of life and in the postoperative
period. Thus, a clinically relevant infection occurred during
the postoperative period in 18 patients, consisting of sepsis
in 9 patients, pneumonia in 7 patients, tracheitis in 4
patients, endocarditis in 2 patients, and meningitis in 1
patient. Eight children experienced more than one
infection.
Thrombocytopenia (less than 100,000 G/l), described
for eight patients, was the most common abnormal finding
49 pts 
CHD + 22q11.2 
40
cardiac surgery 
9
no cardiac surgery 
15
surgical
palliation
5
palliated
no repair 
10
surgical
repair
25
surgical
repair
Fig. 1 Clinical management of congenital heart defect (CHD)
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during midterm follow-up assessment. In one case, an
acute severe thrombocytopenia was caused by a toxic
shock syndrome associated with pneumonia. One girl
required splenectomy as treatment for chronic recurrent
thrombocytopenia. In the remaining six cases, thrombo-
cytopenia did not cause any complications, but it was
recommended to avoid drugs which could potentially
impair platelet function, and to check the platelet count
regularly, particularly if surgery was planned.
Discussion
The prevalence of microdeletion 22q11.2 in CHD pre- and
postnatally and the phenotypic features of the syndrome
have been reported for pediatric and adult patients [3, 5, 16,
Table 3 Causes of death
Patient CHD Extracardiac anomalies Cause of death Age at death
1 PA/VSD Lymphocytopenia, velopharyngeal
incompetence, developmental delay,
psychiatric disorder
Cardiac cause/perioperative 6 years
2 PA/VSD Thymic aplasia, thrombocytopenia, blindness
(microphthalmia, cataract), severe
developmental delay, renal agenesis
Cardiac cause/sudden death 1.8 years
3 PA/VSD Lymphocytopenia, hypoparathyroidism,
renal agenesis
Cardiac cause/perioperative 3 months
4 IAA Lymphocytopenia Cardiac cause/perioperative 4 days
5 Truncus arteriosus communis Dysplastic ears Cardiac cause before surgery 2 days
6 Truncus arteriosus Lymphocytopenia, thrombocytopenia,
splenomegaly, developmental delay
Immunologic cause 4.9 years
7 VSD Severe immunologic disorder, pancytopenia,
developmental delay, brain malformations,
renal agenesis, hydronephrosis
Immunologic cause 2 years
8 Absent PV syndrome Thymic hypoplasia, tracheobronchomalacia,
uvula bifida, brain malformations
Multiple malformations 3 days
9 IAA Lymphocytopenia, hypoparathyroidism Cardiac cause/postoperative
intracranial bleeding,
multiorgan failure
11 days
10 PA/VSD Hypoparathyroidism Postoperative sepsis, pulmonary
complications, repeated CPR
7 months
11 IAA Brain and skeletal malformations,
microphthalmia and cataract cleft palate
Multiple malformations 1 day
CHD, congenital heart defect; PA, pulmonary atresia; VSD, ventricular septal defect; IAA, interrupted aortic arch; PV, pulmonary valve; CPR,
cardiopulmonary reanimation
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Fig. 2 Survival curve for the 49 patients with microdeletion 22q11.2
and congenital heart defect (CHD)
Table 4 Cardiac reinterventions and residual cardiac lesions at the
end of the follow-up period in 35 patients after total repair
Anatomic
lesion
Surgery Interventional
catheterization
Residual
findings
RVOT 8 3 6
PPS 1 8 8
LVOT 3 — 3
Aortic arch — 1 1
VSD 3 — 6
Total 15 12 24
RVOT, right ventricular outflow tract; PPS, peripheral pulmonary
stenosis; LVOT, left ventricular outflow tract; VSD, ventricular septal
defect
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24, 26]. More recently, a few reports have assessed the
influence of deletion 22q11.2 on the outcome for patients
with a specific cardiac lesion [8, 21, 22].
Our data demonstrate that when microdeletion 22q11.2
and CHD are diagnosed during childhood, the cases are
complex, mainly due to the severity of CHD and the
additional extracardiac anomalies. Most of these cases
required repeated surgery, repeated cardiac surgery, long
hospitalization time, additional diagnostic and therapeutic
interventions, and most importantly were associated with
significant morbidity and mortality. As determined by
comparative data on the overall phenotype of children and
adults with microdeletion 22q11.2, these subjects certainly
represent the most severe end of the spectrum and have a
correspondingly poor outcome [24, 26]. Therefore, our
results are different from those published for the adult
population, who may present with less severe ‘‘later rec-
ognized’’ clinical features [3].
The cardiac defects occurring in our cohort were similar
to the spectrum described by other groups, with tetralogy of
Fallot and its variances, interrupted aortic arch, and truncus
arteriosus communis representing the most commonly
observed anomalies [13, 14]. Aortic arch anomalies were
the most frequent additional cardiac malformations [22].
The mortality rate found for our patients was similar to that
reported for surgical repair of interrupted aortic arch (31%)
[27], but slightly higher than that described for pulmonary
atresia and ventricular septal defect (15–22%) [7, 19] and
for truncus arteriosus (13–17%) [6, 28]. It should be noted
that studies reporting the outcome of selected conotruncal
malformations did not differentiate between patients with
and those without the microdeletion 22q11.2, and therefore
are not completely comparable with our study [6, 9, 27]. In
fact, other authors demonstrated that monosomy of a seg-
ment within chromosome band 22q11.2 may represent a
significant risk for perioperative death [1, 18].
A typical pulmonary vascular phenotype, consisting of
hypoplastic pulmonary arteries and a higher occurrence of
major aortopulmonary collaterals, has been described in
patients with microdeletion 22q11.2 and tetralogy of Fallot
or pulmonary atresia and ventricular septal defect [8, 18].
The anatomy of the pulmonary vessels has been identified
as an important risk factor for mortality and for reinter-
ventions in patients undergoing repair of tetralogy of Fallot
and its variances [15, 21]. The high rate of reinterventions
found in our study confirms these data. Similarly, the
presence of associated cardiac anomalies has been dem-
onstrated to be a risk factor for truncus arteriosus repair [6,
15].
The cause of death was cardiac related in only 54% of
the cases. Thus, extracardiac anomalies seem to have a
crucial influence on morbidity and mortality (Table 2). The
prevalence of cases requiring tracheal cannulation was
significantly higher among patients with CHD and mic-
rodeletion 22q11.2 (14%) than among patients with CHD
but no microdeletion 22q11.2 (0.5%). Laryngotracheo-
bronchial malformations, found frequently in children with
microdeletion 22q11.2, may explain the need for cannula-
tion and long-term ventilation [29].
Besides the anomalies influencing the periopera-
tive course, neurodevelopmental retardation, learning
disabilities, and immunohematologic disease frequently
characterized the clinical picture during mid- to long-term
follow-up. The retrospective nature of the study did not
allow us to evaluate this particular aspect in detail because
the importance of neurodevelopmental and social outcome
has been recognized only recently and still is a subject of
evaluation. Moreover, psychosocial deficits may become
more evident during adulthood, when the patients are
expected to function more independently in daily life [23].
Another burden for these patients is the risk for developing
significant psychological disabilities, with schizophrenia
occurring in up to 30% of the adult patients [3, 12, 17].
The presence of a microdeletion 22q11.2 can be sus-
pected prenatally if the fetal ultrasonographic examination
shows a conotruncal heart malformation and an absent or
hypoplastic thymus [2]. A prenatal cytogenetic examina-
tion including FISH analysis then is recommended because
the presence of an interstitial deletion may have a major
impact on the decision of the parents to continue or ter-
minate the pregnancy [5]. For counseling of the families,
the results of our study add important information about the
course of the cardiac disease in this group of patients and
about the associated extracardiac malformations that may
have a major influence on the outcome.
The need for postnatal cytogenetic screening for all
patients with conotruncal malformations has been a subject
of debate [10, 14]. Because early detection of microdele-
tion 22q11.2 may enable better risk stratification, allow
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Fig. 3 Reintervention-free survival of 35 patients after surgical
repair of congenital heart defect (CHD)
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adequate management strategies, avoid potential compli-
cations, and facilitate counseling of the families, we
suggest genetic testing for all newborns with a conotruncal
malformation suggesting the presence of a microdeletion or
another cardiac defect associated with facial
dysmorphisms.
Limitations
The retrospective design of this study based on clinical
records as the only available source of data limits the
quality of information about the clinical course of the
patients. For instance, retrospectively, it was not possible to
determine precisely which one of the postoperative com-
plications may have been the real cause for a prolonged
ICU stay.
As the combination of CHD and microdeletion 22q11.2
represents a rare condition, we assessed a long period of
time, in order to evaluate an adequate number of patients.
Thus, during the initial years, some cases less severely
affected may have not been correctly identified, and a
selection bias may have influenced morbidity and mortality
rates. Moreover, the clinical and surgical treatment of such
complex CHD has improved during the past decade,
potentially leading to better current results.
Finally, during the same period of time, the rarity of the
condition did not allow us to create a matched group of
patients with the same CHD but no microdeletion 22q11.2
for comparison of outcomes. Thus, comparison of out-
comes was based on data reported in the literature [6, 9, 27,
28].
Conclusion
Patients with microdeletion 22q11.2 and CHD present high
morbidity and mortality. These are mainly determined by
the severity of the CHD. Nevertheless, the presence of the
microdeletion and the related extracardiac anomalies con-
tribute to significant morbidity and may influence
mortality. Knowledge of the cardiac outcome and the risks
for complications related to the microdeletion 22q11.2
syndrome may be crucial for appropriate management of
these patients during the perioperative period and for
counseling of the families. Careful repeated cardiac and
neurodevelopmental evaluation is recommendable during
follow-up evaluation.
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